Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › navitoclax

navitoclax

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of navitoclax

2 trials tracked of navitoclax: 1 in phase 3 or 4.

2Trials tracked
1Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 3 1 Phase 2 1
  1. Phase 3 Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis Completed
  2. Phase 2 A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis Completed

Showing the 2 most-cited and recently-updated of 2 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Narrative review proposes phenotype-driven framework for managing myelofibrosis splenomegaly
Cardiology Sys. Review
Narrative review proposes phenotype-driven framework for managing myelofibrosis splenomegaly New combo strategies shrink spleens better than older treatments for myelofibrosis
This narrative review addresses the management of splenomegaly in patients with myelofibrosis. The authors synthesize evidence regarding eme…
Emerging combination strategies like pelabresib plus ruxolitinib or navitoclax plus ruxolitinib show superior spleen shrinkage for myelofibr…
Frontiers May 26, 2026
Phase 3 trial of navitoclax plus ruxolitinib versus ruxolitinib alone in myelofibrosis posts results
Oncology Phase III
Phase 3 trial of navitoclax plus ruxolitinib versus ruxolitinib alone in myelofibrosis posts results Phase 3 trial tests navitoclax with ruxolitinib for myelofibrosis spleen volume
A phase 3 randomized controlled trial in 252 adults with myelofibrosis compared navitoclax plus ruxolitinib to ruxolitinib plus placebo.
A new drug combination aims to shrink painful enlarged spleens in myelofibrosis patients, but results from this large global trial are not y…
CT.gov Apr 2, 2026